Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BeiGene Ltd ( (HK:6160) ) has provided an announcement.
BeOne Medicines has granted 21,034 restricted share units, equivalent to 273,442 underlying shares or about 0.02% of its issued share capital, to 246 employees under its 2016 Share Option and Incentive Plan. The RSUs, which require no consideration from recipients and generally vest in 25% annual tranches over four years with potential acceleration on termination or change of control, exclude directors, chief executives and substantial shareholders, carry no performance targets or clawback, and are framed by the board’s compensation committee as market-competitive and aligned with the plan’s objectives, leaving more than 60.9 million shares available for future equity-based awards.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$219.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
BeOne Medicines Ltd., incorporated in Switzerland and listed in Hong Kong, operates in the biopharmaceutical sector and uses share-based incentive schemes to attract and retain employees across its group. The company maintains a 2016 Share Option and Incentive Plan that allows it to grant restricted share units (RSUs) and other equity awards as part of its long-term compensation strategy.
Average Trading Volume: 3,949,670
Technical Sentiment Signal: Buy
Current Market Cap: HK$337.8B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.